Abdelmasih R, Abdelmaseih R, Thakker R, et al. Update on the cardiovascular benefits of sodium-glucose co-transporter-2 Inhibitors: mechanism of action, available agents and comprehensive review of literature. Cardiol Res. 2021;12:210–8.

Article  PubMed  PubMed Central  Google Scholar 

Seufert J. SGLT2 inhibitors-an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015;8:543–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chilton R, Tikkanen I, Hehnke U, et al. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2017;19:1620–4.

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752–72.

Article  CAS  PubMed  Google Scholar 

Leiter LA, Cefalu WT, de Bruin TWA, et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. 2016;18:766–74.

Article  CAS  PubMed  Google Scholar 

Lai S-W. Gout and sodium-glucose cotransporter-2 inhibitors. Pharmacoepidemiol Drug Saf. 2022;31:112–3.

Article  CAS  PubMed  Google Scholar 

Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431–46.

Article  CAS  PubMed  Google Scholar 

Mikuls TR. Gout. N Engl J Med. 2022;387:1877–87.

Article  PubMed  Google Scholar 

Kuo C-F, Grainge MJ, Mallen C, et al. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75:210–7.

Article  PubMed  Google Scholar 

Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62:3307–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Y, Hu Y, Huang T, et al. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem Biophys Res Commun. 2014;447:707–14.

Article  CAS  PubMed  Google Scholar 

Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391–404.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McNally JS, Saxena A, Cai H, et al. Regulation of xanthine oxidoreductase protein expression by hydrogen peroxide and calcium. Arterioscler Thromb Vasc Biol. 2005;25:1623–8.

Article  CAS  PubMed  Google Scholar 

Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9.

Article  CAS  PubMed  Google Scholar 

Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845–54.

Article  CAS  PubMed  Google Scholar 

Xin Y, Guo Y, Li Y, et al. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis. Saudi J Biol Sci. 2019;26:421–6.

Article  CAS  PubMed  Google Scholar 

Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20:458–62.

Article  CAS  PubMed  Google Scholar 

Yip ASY, Leong S, Teo YH, et al. Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. Ther Adv Chronic Dis. 2022;13:20406223221083508.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:422–34.

Article  CAS  PubMed  Google Scholar 

Liang AL, Gingher EL, Coleman JS. Medical cannabis for gynecologic pain conditions: a systematic review. Obstet Gynecol. 2022;139:287–96.

Article  PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.

Article  PubMed  Google Scholar 

National Center for Biotechnology Information. Newcastle-Ottawa Quality Assessment Form for Cohort Studies [Internet]. [cited 2024 Mar 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK115843/figure/appe.fm3/?report=objectonly.

Röver C. Bayesian random-effects meta-analysis using the bayesmeta R package. J Stat Softw. 2017;93(6):1–51.

Article  Google Scholar 

Greco T, Landoni G, Biondi-Zoccai G, et al. A Bayesian network meta-analysis for binary outcome: how to do it. Stat Methods Med Res. 2016;25:1757–73.

Article  PubMed  Google Scholar 

Chaimani A, Higgins JPT, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS ONE. 2013;8: e76654.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Badve SV, Zhou Z, et al. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatol. 2019;1:e220–8.

Article  PubMed  Google Scholar 

Ferreira JP, Inzucchi SE, Mattheus M, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022;24:135–41.

Article  CAS  PubMed  Google Scholar 

Doehner W, Anker SD, Butler J, et al. Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J. 2022;43:3435–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61.

Article  CAS  PubMed  Google Scholar 

Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928–38.

Article  CAS  PubMed  Google Scholar 

Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473–8.

Article  CAS  PubMed